Sharechat Logo

AFT Pharmaceuticals to announce full year results on Monday

Thursday 4th May 2023

Text too small?

AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023. The release will be issued at around 09:00.

 

This will be followed by a presentation by management at 10:00 by teleconference. The presentation material which will be referred to by management will be issued at around 09:00 and will also be available on the company’s website aftpharm.com.

 

To attend the conference call you will need to use the pre-registration link below. Once you have completed this you will be provided with dial in details and a unique pin code.

 

Registration Link: AFT results presentation FY2023

 

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

 

For more information:

 

Investors Media

Malcolm Tubby Richard Inder

CFO, AFT Pharmaceuticals Ltd The Project

Phone: +64 9 488 0232 Phone: 021 645 643

Email: malcolm@aftpharm.com Email: richard@theproject.co.nz

 

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

PFI Announces Annual Results
SUM - Financial Results for the Year Ended 31 December 2023
GMT positioned for growth with Internalisation Proposal
Bright Dairy Director appointed
February 26th Morning Report
BLT - Revenue Growth and Profitable Third Quarter
MOVE Logistics Group - 1H24 Results
TRU - CEO Resignation and Interim CEO Appointment
JLG - Preliminary Half-Yearly Result and Trading Update
February 23rd Morning Report